沙库巴曲缬沙坦及达格列净联合螺内酯治疗射血分数降低心力衰竭的疗效分析

Efficacy Analysis of Sacubitril,Valsartan and Dapagliflozin Combined with Spironolactone in the Treatment of Heart Failure with Reduced Ejection Fraction

目的探析射血分数降低的心力衰竭(HFrEF)患者接受沙库巴曲缬沙坦及达格列净联合螺内酯治疗的临床疗效。方法选取2019年6月—2020年6月该院收治的64例射血分数降低心力衰竭患者为研究对象,经数字表法分组,32例患者采取厄贝沙坦联合螺内酯治疗为对照组,32例入选采取沙库巴曲缬沙坦、达格列净及螺内酯联合治疗为观察组,评估患者组间心功能、临床疗效,检测患者血清生化指标。结果观察组经治疗,LVEDD(41.47±2.34)mm、LVESD(34.67±1.89)mm、LVEF(49.92±4.05)%和对照组相比,差异有统计学意义(P<0.05);观察组经治疗,显效率为84.38%,明显强于对照组,差异有统计学意义(χ^(2)=3.925,P<0.05);观察组经治疗,NT-proBNP(401.26±6.89)pg/mL、醛固酮(68.69±5.76)pg/mL,均少于对照组,差异有统计学意义(P<0.05)。结论射血分数降低的心力衰竭患者接受沙库巴曲缬沙坦、达格列净及螺内酯联合治疗,其心功能、临床疗效明显优于厄贝沙坦联合螺内酯治疗患者。

Objective To analyze the clinical efficacy of sacubitril valsartan and dapagliflozin combined with spironolactone in patients with heart failure(HFrEF)with reduced ejection fraction.Methods 64 patients with heart failure with reduced ejection fraction treated in the hospital from June 2019 to June 2020 were selected as the research objects.Grouped by number table,32 patients treated with irbesartan combined with spironolactone were selected as the control group.Thirty-two patients treated with sacubitril,valsartan,dapagliflozin,and spironolactone were selected as the observation group.Evaluated the cardiac function and clinical efficacy between groups of patients,and detected the serum biochemical indicators of patients.Results After treatment,LVEDD(41.47±2.34)mm,LVESD(34.67±1.89)mm,LVEF(49.92±4.05)%in the observation group were compared with those in the control group,and the difference was statistically significant(P<0.05).After treatment,the effective rate was 84.38%in the observation group,which was significantly stronger than that of the control group,and the difference was statistically significant(χ^(2)=3.925,P<0.05).After treatment,the NT-proBNP(401.26±6.89)pg/mL and aldosterone(68.69±5.76)pg/mL in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Patients with heart failure with reduced ejection fraction received sacubitril valsartan,dapagliflozin and spironolactone combined treatment.Its cardiac function and clinical efficacy are significantly better than those of irbesartan combined with spironolactone.